In high­ly un­usu­al op-ed, 3 ad­u­canum­ab ad­comm mem­bers again call on FDA to re­ject Bio­gen's Alzheimer's drug

Typ­i­cal­ly, when the FDA con­venes ad­vi­so­ry com­mit­tees for drugs or vac­cines, the out­side ex­perts of­fer their per­spec­tive, vote, and then the agency ei­ther lis­tens to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.